Effect of zafirlukast on methacholine and ultrasonically nebulized distilled water challenge in patients with mild asthma

P. Carratù, N. Morelli, Amado Freire, Muthiah Muthiah, S. Guerra, Reba Umberger, L. Allegra

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Bronchial asthma is a chronic inflammatory disease characterized by airway inflammation and hyperresponsiveness due to the release of multiple mediators, such as cysteinyl-leukotrienes (cys-LTs). Objective: Our study was designed to investigate whether oral pretreatment with zafirlukast (a cys-LTs receptor antagonist) reduces bronchoconstriction against methacholine (MC) and ultrasonically nebulized distilled water (UNDW) challenge in patients with mild asthma. Methods: Fourteen non-atopic patients (8 males, 20-42 years, forced expiratory volume in 1 s (FEV1) 97% SD ± 0.4) with mild, intermittent bronchial asthma performed a sequential weekly pulmonary function test following challenge with MC or UNDW 2 h after zafirlukast or placebo administration, according to a single-blind method. Results: We found that pretreatment with zafirlukast significantly decreased bronchoconstriction MC (maximum FEV1 drop -10.75% SD ± 1.89, p < 0.001) and UNDW induced (maximum FEV1 drop -12% SD ± 0.15, p < 0.001), while pre-treatment with placebo did not protect patients against FEV 1 drop following MC (maximum FEV1 drop -33.22% SD ± 1.42, p < 0.001) and UNDW challenge (maximum FEV1 drop -30.02% SD ± 0.4, p < 0.001). Conclusions: Pretreatment with zafirlukast significantly reduced bronchoconstriction against MC and UNDW challenge in individuals with mild intermittent asthma, indicating that cys-LTs receptor antagonists might be useful as preventive therapy in these patients population.

Original languageEnglish (US)
Pages (from-to)249-253
Number of pages5
JournalRespiration
Volume70
Issue number3
DOIs
StatePublished - Aug 22 2003

Fingerprint

Methacholine Chloride
Forced Expiratory Volume
Asthma
Bronchoconstriction
Water
Leukotriene Antagonists
Placebos
Single-Blind Method
Respiratory Function Tests
Chronic Disease
zafirlukast
Inflammation
Therapeutics
Population

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Effect of zafirlukast on methacholine and ultrasonically nebulized distilled water challenge in patients with mild asthma. / Carratù, P.; Morelli, N.; Freire, Amado; Muthiah, Muthiah; Guerra, S.; Umberger, Reba; Allegra, L.

In: Respiration, Vol. 70, No. 3, 22.08.2003, p. 249-253.

Research output: Contribution to journalArticle

@article{3cbc89adda41404e8f71861c50bb48b2,
title = "Effect of zafirlukast on methacholine and ultrasonically nebulized distilled water challenge in patients with mild asthma",
abstract = "Background: Bronchial asthma is a chronic inflammatory disease characterized by airway inflammation and hyperresponsiveness due to the release of multiple mediators, such as cysteinyl-leukotrienes (cys-LTs). Objective: Our study was designed to investigate whether oral pretreatment with zafirlukast (a cys-LTs receptor antagonist) reduces bronchoconstriction against methacholine (MC) and ultrasonically nebulized distilled water (UNDW) challenge in patients with mild asthma. Methods: Fourteen non-atopic patients (8 males, 20-42 years, forced expiratory volume in 1 s (FEV1) 97{\%} SD ± 0.4) with mild, intermittent bronchial asthma performed a sequential weekly pulmonary function test following challenge with MC or UNDW 2 h after zafirlukast or placebo administration, according to a single-blind method. Results: We found that pretreatment with zafirlukast significantly decreased bronchoconstriction MC (maximum FEV1 drop -10.75{\%} SD ± 1.89, p < 0.001) and UNDW induced (maximum FEV1 drop -12{\%} SD ± 0.15, p < 0.001), while pre-treatment with placebo did not protect patients against FEV 1 drop following MC (maximum FEV1 drop -33.22{\%} SD ± 1.42, p < 0.001) and UNDW challenge (maximum FEV1 drop -30.02{\%} SD ± 0.4, p < 0.001). Conclusions: Pretreatment with zafirlukast significantly reduced bronchoconstriction against MC and UNDW challenge in individuals with mild intermittent asthma, indicating that cys-LTs receptor antagonists might be useful as preventive therapy in these patients population.",
author = "P. Carrat{\`u} and N. Morelli and Amado Freire and Muthiah Muthiah and S. Guerra and Reba Umberger and L. Allegra",
year = "2003",
month = "8",
day = "22",
doi = "10.1159/000072005",
language = "English (US)",
volume = "70",
pages = "249--253",
journal = "Respiration; international review of thoracic diseases",
issn = "0025-7931",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Effect of zafirlukast on methacholine and ultrasonically nebulized distilled water challenge in patients with mild asthma

AU - Carratù, P.

AU - Morelli, N.

AU - Freire, Amado

AU - Muthiah, Muthiah

AU - Guerra, S.

AU - Umberger, Reba

AU - Allegra, L.

PY - 2003/8/22

Y1 - 2003/8/22

N2 - Background: Bronchial asthma is a chronic inflammatory disease characterized by airway inflammation and hyperresponsiveness due to the release of multiple mediators, such as cysteinyl-leukotrienes (cys-LTs). Objective: Our study was designed to investigate whether oral pretreatment with zafirlukast (a cys-LTs receptor antagonist) reduces bronchoconstriction against methacholine (MC) and ultrasonically nebulized distilled water (UNDW) challenge in patients with mild asthma. Methods: Fourteen non-atopic patients (8 males, 20-42 years, forced expiratory volume in 1 s (FEV1) 97% SD ± 0.4) with mild, intermittent bronchial asthma performed a sequential weekly pulmonary function test following challenge with MC or UNDW 2 h after zafirlukast or placebo administration, according to a single-blind method. Results: We found that pretreatment with zafirlukast significantly decreased bronchoconstriction MC (maximum FEV1 drop -10.75% SD ± 1.89, p < 0.001) and UNDW induced (maximum FEV1 drop -12% SD ± 0.15, p < 0.001), while pre-treatment with placebo did not protect patients against FEV 1 drop following MC (maximum FEV1 drop -33.22% SD ± 1.42, p < 0.001) and UNDW challenge (maximum FEV1 drop -30.02% SD ± 0.4, p < 0.001). Conclusions: Pretreatment with zafirlukast significantly reduced bronchoconstriction against MC and UNDW challenge in individuals with mild intermittent asthma, indicating that cys-LTs receptor antagonists might be useful as preventive therapy in these patients population.

AB - Background: Bronchial asthma is a chronic inflammatory disease characterized by airway inflammation and hyperresponsiveness due to the release of multiple mediators, such as cysteinyl-leukotrienes (cys-LTs). Objective: Our study was designed to investigate whether oral pretreatment with zafirlukast (a cys-LTs receptor antagonist) reduces bronchoconstriction against methacholine (MC) and ultrasonically nebulized distilled water (UNDW) challenge in patients with mild asthma. Methods: Fourteen non-atopic patients (8 males, 20-42 years, forced expiratory volume in 1 s (FEV1) 97% SD ± 0.4) with mild, intermittent bronchial asthma performed a sequential weekly pulmonary function test following challenge with MC or UNDW 2 h after zafirlukast or placebo administration, according to a single-blind method. Results: We found that pretreatment with zafirlukast significantly decreased bronchoconstriction MC (maximum FEV1 drop -10.75% SD ± 1.89, p < 0.001) and UNDW induced (maximum FEV1 drop -12% SD ± 0.15, p < 0.001), while pre-treatment with placebo did not protect patients against FEV 1 drop following MC (maximum FEV1 drop -33.22% SD ± 1.42, p < 0.001) and UNDW challenge (maximum FEV1 drop -30.02% SD ± 0.4, p < 0.001). Conclusions: Pretreatment with zafirlukast significantly reduced bronchoconstriction against MC and UNDW challenge in individuals with mild intermittent asthma, indicating that cys-LTs receptor antagonists might be useful as preventive therapy in these patients population.

UR - http://www.scopus.com/inward/record.url?scp=0041571549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041571549&partnerID=8YFLogxK

U2 - 10.1159/000072005

DO - 10.1159/000072005

M3 - Article

VL - 70

SP - 249

EP - 253

JO - Respiration; international review of thoracic diseases

JF - Respiration; international review of thoracic diseases

SN - 0025-7931

IS - 3

ER -